Oncology / Acute Myeloid Leukemia
Indication
Acute Myeloid Leukemia
Assets addressing this indication.
Total attributable cost
$4.3B
$190,305/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US
Oncology / Acute Myeloid Leukemia
Indication
Assets addressing this indication.
Total attributable cost
$4.3B
$190,305/patient
Drug spend
Not yet sourced
All stages, newly diagnosed (2026 incidence estimate) · US
127 of 127 assets